



Novartis India Limited
Registered Office:
Sandoz House
Shivsagar Estate
Dr. Annie Besant Road
Worli, Mumbai 400 018
India
Tel +91 22 2495 8400
Fax +91 22 2495 0221
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

July 12, 2018

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Dear Sirs,

Subject: Update with respect to a newspaper publication in Mint on July 12, 2018

This letter has a reference to a newspaper publication in 'Mint' on July 12, 2018 regarding issuance of a show cause notice by drug licensing authority to Themis Medicare Limited (Themis), who is a manufacturer of Diclofenac 1 ml injection for Novartis India Limited (Company).

In this context, it may be noted that Themis has intimated the Company on July 12, 2018 that they are in receipt of a show cause notice dated July 11, 2018 from the drug licensing authority at Daman, wherein they were directed to not manufacture the said product until the matter is decided.

Themis has been manufacturing Diclofenac 1 ml injection under Voveran brand since 2015 and has been marketed by the Company in India based on regulatory approvals granted to them earlier. The Company has sold over 110 million ampoules of this SKU with no serious adverse events reported.

We also understand that Themis is independently pursuing a writ petition already filled by them in the Delhi High Court pertaining to the said issue.

Novartis is committed to providing patients with high quality medicines and patient safety is at the core of everything we do.

Kindly to take note of the above in your records.

Thanking you

For Novartis India Limited



Trivikram Guda
Company Secretary &
Compliance Officer